3Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin, 2009, 59: 225-249.
4Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc, 1975, 50: 29-40.
5Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oneol, 2005, 23:3412-3420.
6Tiedemann RE, Mao X, Shi CX, et al. Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. J Clin Invest, 2008,118: 1750-1764.
7Carrasco DR, Tonon G, Huang Y, et al. High-resolution genomic profiles define distinct clinic-pathogenetic subgroups of multiple myeloma patients. Cancer Cell, 2006, 9: 313-325.
8Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood, 2007, 109: 3489-3495.
9Chng W J, Santana-Davila R, Van Wier SA, et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia, 2006, 20: 807-813.
10Hideshima T, Bergsagel PL, Kuehl WM, et al. Advances in biology of multiple myeloma: clinical applications. Blood, 2004, 104: 607-618.
